Login
$TELA
$0.76 -$0.06 (7.13%) Live

$TELA 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

MALVERN, PA, November 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter end...

08 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

On October 8, 2026, TELA Bio, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). As of September 8, 2026, the record date for the Special Meeting, there were 45,143,410 outstanding shares of the Company’...

06 Oct 2026 8-K: Other Events

On October 5, 2026, TELA Bio, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Mark...

05 Oct 2026 8-K: Other Events

MALVERN, PA, October 5, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug...

29 Sep 2026 8-K: Entry into a Material Definitive Agreement

On September 28, 2026, TELA Bio, Inc. (the “Company”) entered into a Limited Consent to Credit Agreement and Guaranty (the “Limited Consent”) with Perceptive Credit Holdings V, LP, as administrative agent and collateral agent (the “Admin...

18 Sep 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

31 Aug 2026 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more

Company to reduce annual operating expenses by $17.0 million or 18%

10 Aug 2026 8-K: Results of Operations and Financial Condition

MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ende...

04 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

11 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

WHEREAS, the Board of Directors of TELA Bio, Inc., a Delaware corporation (the “Company”) approved and adopted the Amended and Restated 2019 Equity Incentive Plan (the “2019 Plan”) of the Company on April 20, 2020;

12 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

MALVERN, PA, May 12, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended Ma...

30 Apr 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

On April 29, 2026, TELA Bio, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue for the quarter ended March 31, 2026 of approximately $19.0 million. The Company has not yet completed its quarter-end ...

24 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

MALVERN, PA, March 24, 2026 -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and f...

20 Mar 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

14 Nov 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both (i) not material and (ii) the type of information that the Registrant treats as private or confid...

13 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

MALVERN, PA, November 13, 2025 -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter end...

03 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

09 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

11 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

MALVERN, PA, August 11, 2025 -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ende...

02 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

MALVERN, PA – June 2, 2025 – TELA Bio, Inc. ("TELA Bio") a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support